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Abstract
In the medically inoperable patients with solitary hepatocellular carcinoma (HCC), local 
therapies, such as radiofrequency ablation and transarterial chemoembolization, are used 
as alternatives. However, several factors, including anatomic and vascular variants, make 
procedures more challenging. Radiotherapy has historically been used as a palliative option 
for unresectable HCC. However, recent advances in modern radiotherapy, such as stereo-
tactic body radiation therapy (SBRT), have dramatically increased the use of radiotherapy 
as a curative modality, particularly in cases ineligible for local ablation therapy or surgical 
resection. SBRT is a modern approach for delivering ablative high doses of irradiation in 
small volumes. SBRT in liver tumors, including HCC, provided local control with potential 
survival benefits in patients with inoperable status. However, the following issues remain 
to be addressed: the difference between primary and metastatic liver cancers; SBRT-related 
toxicity and prevention; pathological features of liver cancers; and potential SBRT strate-
gies, including radiobiology-based SBRT and SBRT combined with immunotherapy. We 
summarized the effectiveness of SBRT and patient tolerance of the therapy. In addition, we 
present the current status and future perspective of SBRT as a treatment option for HCC.
Keywords: radiotherapy, stereotactic body radiation therapy, stereotactic ablative 
radiotherapy, hepatocellular carcinoma, cirrhosis, liver
1. Introduction
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver [1]. 
Liver cancers have the seventh highest age-adjusted incidence rate in the world, with 0.8 mil-
lion cases diagnosed a year [2]. The development of cirrhosis is associated with a high risk 
for developing HCC with most common risk factors including alcohol, viral hepatitis such 
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as hepatitis C virus (HCV), and nonalcoholic fatty liver disease (NAFLD). Due to the wide 
prevalence of HCC, it carries a significant economic burden on society at large, especially in 
the East Asian countries that have hepatitis B virus (HBV). Surveillance programs halve also 
been implemented to screen for HCC in high-risk individuals, which is more cost-effective 
than the treatment of HCC. Hepatotropic viruses such as HBV and HCV have a strong asso-
ciation with the development of HCC; thus, the worldwide distribution of HCC mirrors the 
distributions of such viral infections [3]. Around 80–90% of HCC cases occur in the setting 
of underlying cirrhosis [4]. In addition, there is an incremental effect of the presence of more 
than one risk factor responsible for HCC as the presence of HBV/HCV coinfections increases 
the risk of HCC by two- to sixfolds. Similarly, alcohol abuse further increases this risk [5, 6]. 
Subsequently, we describe the role of radiotherapy in the treatment of HCC, including con-
ventional to modern techniques, possible beneficial cases of radiotherapy, and future direc-
tion of liver stereotactic body radiation therapy (SBRT).
2. General approaches and conventional radiotherapy in the 
treatment of HCC
The initial approach in the management of HCC is to determine if either surgical resection or 
liver transplantation is feasible and best survival. The Barcelona Clinic Liver Cancer staging 
system is the most accepted staging system in clinical settings [7]. Orthotopic liver trans-
plantation is the most efficient option for the treatment of HCC even though the insufficient 
number of donors makes challenging [8]. Therefore, local therapy is anticipated to be not only 
a bridging therapy but also a radical therapy in the treatment of HCC. Surgical resection is 
the standard local therapy for HCC [7]. Since the majority of HCC cases develop in cirrhotic 
patients, surgical interventions can become challenging, and the treatment has been directed 
toward liver transplantation. Other local therapies, such as radiofrequency ablation (RFA) 
and transarterial chemoembolization (TACE), are used as alternatives in patients with HCC 
[7–9]. However, radical treatment for liver tumors can be challenging due to poor liver func-
tion, tumor location, and anatomical barriers. Furthermore, the preservation of residual liver 
function is required, as liver tumors have a high recurrence potential [9].
Radiotherapy is a local treatment modality and has also been used for palliative care in liver 
tumors. Conventional radiotherapy has been used approximately 50 Gy in a conventional 
fractionated schedule which could lead to a response rate as approximately 50–70% [10–14]. 
High doses of radiation, which are required for HCC, would sometimes exceed the levels 
tolerated by the background liver [15, 16]. However, modern radiotherapies, including ste-
reotactic body radiation therapy (SBRT), also known as stereotactic ablative radiation therapy 
(SABR), have recently attracted increasing attention as a therapeutic modality for various 
malignancies including HCC and have dramatically increased the use of radiation therapy 
as a curative modality [17–40]. However, certain issues regarding the current use of SBRT in 
HCC need to be addressed (e.g., ideal prescription doses, prevention of adverse events, and 
possible microscopic extension). In this chapter, we document the clinical utility and the pres-
ent status of SBRT in the management of HCC, including clinical messages and pitfalls in liver 
cirrhosis and the probable treatment-related toxicities and their prevention, and summarize 
recent significant updates on biology-based SBRT strategies.
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3. SBRT for HCC
The use of SBRT for extracranial tumors was developed by Blomgren et al. [17]. The major 
feature that distinguishes SBRT from conventional radiation treatment is the delivery of large 
doses of radiation in a few fractions, which results in a high biologically effective dose (BED). 
In addition, Zheng et al. have reported that a shortened delivery time could significantly 
increase the cell killing using in vitro experimentation [41]. The use of a high precision tech-
nique is critical to deliver a high dose of radiation to the target and keep rapid fall-off doses 
away from the target, thereby achieving a maximum treatment efficacy with minimal toxicity 
to normal tissues [42]. SBRT is now widely accepted as a treatment option for lung and liver 
tumors characterized by their small size and limited numbers [43].
Current advantages and challenges of SBRT in the liver are presented in Table 1. The clini-
cal outcomes of SBRT for HCC in the previous reports are shown in Table 2. SBRT has been 
reported to provide 1-, 2-, and 3-year local control rates of 56–100, 53–95, and 51–92%, and 
1-, 2-, and 3-year survival rates of 32–100, 55–100, and 21–82% for HCC, respectively [19–38]. 
Figure 1 indicates the local control and overall survival after SBRT, BED
10
 ≥ 75 Gy in ≤10 frac-
tions (e.g., 40 Gy/4 fr), for HCC at our institute. Figure 2 indicates a typical course of SBRT 
for HCC in cirrhotic liver. Recent reports indicated that SBRT was as effective as TACE and 
RFA, although there are only a small number of randomized trials examining the use of SBRT 
in HCC [34, 35, 38]. However, additional prospective studies involving large sample sizes are 
required to consolidate the evidences on SBRT with aim to standardize liver SBRT.
Advantages
• High possibility of local control
• Minimally invasive treatment modality, no requirements for anesthesia or injections
• High possibility to overcome anatomical limitations, including poorly defined tumors on ultrasound and tumors 
which are difficult to puncture
• No concern regarding the location close to major vessels, including the portal vein, inferior vein cava, and bile 
duct
• Possible to treat complicated forms of tumors, particularly using IMRT
• Short treatment term (usually within 2 weeks), possibility of benefit to the patient’s quality of life and reduced 
medical cost
• Possibility to enhance the immune reaction to tumors
Current issues
• Poor outcomes and high possibility of toxicity with large tumors
• Challenges involved in the treatment of tumors close to critical organs, such as the gastrointestinal tract
• Effects of re-irradiation are unclear
• Inaccuracy due to respiration and the presence of ascites
Abbreviations: SBRT = stereotactic body radiation therapy; IMRT = intensity modulated radiation therapy.
Table 1. Features of SBRT for liver tumors.
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Author 
[Ref]
Year Prospective/
retrospective
Patient 
number
Total dose/
fraction (median, 
range)
BED
10
 (Gy) Median 
follow-up 
(range) 
(months)
Local 
control
Overall 
survival
Adverse events
Acute response Late response
Kwon 
et al. [19]
2010 Retrospective 42 33 (30-39) Gy/3 fr 
(70–85% isodose 
line covered the 
PTV)
69.2 (60-89.7) 29 1-year 72%
3-year 68%
1-year 
92.9%
3-year 
58.6%
35.7% G1 
Constitutional 
symptoms
31.0% G1-2 Elevated 
liver enzyme
19.0% G1–2 
Leukopenia
2.4% G1 
hyperbilirubinemia 
and ALP
2.4% (1 patient) G4 
Liver failure
Seo et al. 
[20]
2010 Retrospective 38 33-57 Gy/3 fr
or
40-44 Gy/4 fr 
(60.5% patients 
received 39–57 
Gy/3 fr)
69.3-165.3
or
80-92.4 
(89.7–165.3)
15 1-year 78.5%
2-year 66.4%
1-year 
68.4%
2-year
61.4%
3-year 
42.1%
(57.9% G1-2 acute 
toxicities)
10.5% G1-2 
hyperbilirubinemia
2.6% G1 albumin
5.3% G1 AST/ALT
2.6% G1 ALP
44.7% G1–2 Nausea, 
vomiting
7.9% G1 anorexia
13.2% G1–2 
abdominal pain
2.6% G2 Paralytic 
ileus
2.6% G2 radiation 
dermatitis
2.6% G3 soft tissue 
toxicity (the right 
upper quadrate of the 
abdomen)
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Author 
[Ref]
Year Prospective/
retrospective
Patient 
number
Total dose/
fraction (median, 
range)
BED
10
 (Gy) Median 
follow-up 
(range) 
(months)
Local 
control
Overall 
survival
Adverse events
Acute response Late response
Andolino 
et al. [21]
2011 Prospective 60 Child-Pugh A 
(60%): 44 Gy/3 fr
Child-Pugh B 
(40%): 40 Gy/5 fr
(80% isodose line, 
encompassing 
PTV)
Child-Pugh 
A: 108.5
Child-Pugh 
B: 85.5
27 3-year 90% 3-year 
67%
n = 56 (93%)
23.2% G1-2 fatigue, 
nausea, and/or right 
upper quadrant 
discomfort
1.8% G2 chest wall 
toxicity
16.1% G3 liver enzymes 
elevation and/or 
hyperbilirubinemia
16.1% G3 
thrombocytopenia
3.6% PT-INR
12.5% G3 albumin
(17 patients of 21 
patients with G3 
hypoalbuminemia 
preexisting Grade 2 
dysfunction)
1.8% G4 
thrombocytopenia and 
hyperbilirubinemia
20.0% Child-Pugh 
classification 
progression
Kang et al. 
[22]
2012 Prospective 47 57 (42-60) Gy/3 fr
(70–80% isodose 
line covered at 
least 97% of the 
PTV)
165.3 
(100.8–180.0)
17 2-year 94.6% 2-year 
68.7%
4.3% G3 hyperbilirubinemia (pre-existing 
Grade 1 or 2 hyperbilirubinemia and/or 
thrombocytopenia)
10.6% G3 Thrombocytopenia
4.3% G3 Ascites
6.4% G3, 4.3% G4 Gastrointestinal ulcer
(3 of 5 patients had pre-existing ulcer, 2 
patients experienced Grade 4 gastric ulcer 
perforation at 7 months and 10 months after 
SBRT)
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Author 
[Ref]
Year Prospective/
retrospective
Patient 
number
Total dose/
fraction (median, 
range)
BED
10
 (Gy) Median 
follow-up 
(range) 
(months)
Local 
control
Overall 
survival
Adverse events
Acute response Late response
Huang 
et al. [23]
2012 Retrospective 36 37 (25-48) Gy/4-5 
fr (70–83% 
isodose line, 
encompassing 
PTV)
NA(31.2–
105.6)
14 1-year 87.6%
2-year 75.1%
2-year 
64%
36.1% G1-2 fatigue 
25.0% G1-2 anorexia
13.9% G1-2 nausea/
vomiting
5.6% G1-2 
abdominal pain
2.8% G2, 2.8% G3 
gastric ulcer
(Both of 2 patients 
had gastritis before 
SBRT
2.8% G1 
musculoskeletal
5.6% RILD (2 patients 
with Child-Pugh B)
Honda 
et al. [24]
2013 Retrospective 30 48 Gy/4 fr (86.7% 
of patients) or
60 Gy/8 fr (13.3% 
of patients)
(isocenter 
prescription)
105.6
or
105.0
12.3 CR:96.3% 1-year
100%
2-year
100%
93.3% G1-2, 6.7% G3 
leukocytopenia
96.7% G1-2, 3.3% G3 
thrombocytopenia
100% G1–2 
hemoglobin
G1-2 
hyperbilirubinemia
G1 AST/ALT
G1 ALP
3.3% Child-Pugh class 
progression
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Author 
[Ref]
Year Prospective/
retrospective
Patient 
number
Total dose/
fraction (median, 
range)
BED
10
 (Gy) Median 
follow-up 
(range) 
(months)
Local 
control
Overall 
survival
Adverse events
Acute response Late response
Bae et al. 
[25]
2013 Retrospective 35 45 (30-60) Gy/3-5 
fr
(56–83% isodose 
line of the 
maximum dose or 
D95 prescription 
of 91–100% 
prescription doses 
for PTV)
101 (58–180) 14 1-year 69%
3-year 51%
1-year 
52%
3-year 
21%
(23% of patients 
experienced grade ≥ 
3 toxicity)
8.6% G3 AST 
(1 patient also 
had grade 3 
hyperbilirubinemia, 
all patients had pre-
existing grade 2 
elevation of AST or 
hyperbilirubinemia 
and experienced 
progression 
of intrahepatic 
HCC)
2.9% G3 Hepatic 
failure (1 month 
after SBRT)
2.9% G3 colonic 
ulcer (1 month after 
SBRT)
2.9% G4 Myelitis
(18 months after SBRT, 
spine Dmax = 31 Gy/4 
fr)
2.9% G3 gastric ulcer 
perforation (7 months 
after SBRT)
2.9% G5 duodenal ulcer 
bleeding (5 months 
after SBRT)
2.9% G4 colonic ulcer 
(3 months after SBRT)
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Author 
[Ref]
Year Prospective/
retrospective
Patient 
number
Total dose/
fraction (median, 
range)
BED
10
 (Gy) Median 
follow-up 
(range) 
(months)
Local 
control
Overall 
survival
Adverse events
Acute response Late response
Bujold 
et al. [26]
2013 Prospective 102 36 (24-54) Gy/6 fr 57.6 
(33.6–102.6)
31 1-year 87% NA 
(median 
17 
months)
1.0% G3 fatigue
10.9% AST/ALT
3.0% G3, 2.0% G4 hyperbilirubinemia
1.0% G3 creatinine
2.0% G3 hemoglobin
1.0% G3 leukocytes
9.0% G3 platelets
29% (3-month), 6% (12-month) Child-Pugh 
class progression
46% (3-month), 17% (12-month) Child-Pugh 
score progression
1.0% G3, 1.0% G4, 4.9% G5 Liver failure
1.0% G5 cholangitis (HCC invaded the 
common bile duct)
1.0% G3, 1.0% G5 gastritis/gastrointestinal 
bleeding (G5 occurred 7.7 months after 
SBRT)
Jang et al. 
[27]
2013 Retrospective 82 (95 
HCC)
51 (33-60) Gy/3 fr 
(70–80% isodose 
line covered at 
least 97% of the 
PTV)
137.7 
(69.3–180.0)
30 2-year 87%
5-year 82%
2-year 
63%
3-year 
39%
1.2% G3 hyperbilirubinemia (pre-existing 
G1) 2.4% G3 ascites
7.3% non-classic RILD (worsening of CTP 
score by ≥ 2, ≤ 3 months after SBRT, 2 of 6 
with disease progression)
1.2% G3 soft tissue toxicity (this patient had 
a large tumor near the skin)
6.1% G3–4 GI toxicity (gastroduodenal ulcer 
in 2 patients, clonic ulcer in 1 patient, and 
gastroduodenal perforation in 2 patients, 
gastroduodenal perforation in 2 patients)
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Author 
[Ref]
Year Prospective/
retrospective
Patient 
number
Total dose/
fraction (median, 
range)
BED
10
 (Gy) Median 
follow-up 
(range) 
(months)
Local 
control
Overall 
survival
Adverse events
Acute response Late response
Sanuki 
et al. [28]
2014 Retrospective 185 Child-Pugh A 
(74.1%): 40 Gy/5 fr
Child-Pugh B 
(25.9%): 35 Gy/5 fr
(70–80% 
isodose line, 
encompassing 
PTV)
Child-Pugh 
A: 72.0
Child-Pugh 
B: 59.5
24 1-year 99%
2-year 93%
3-year 91%
1-year 
95%
2-year 
83%
3-year 
70%
4.9% mild fatigue
3.2% G3 laboratory 
abnormalities (prior 
to SBRT)
10.3% Child-Pugh 
score progression (by 
two points)
1.1% G5 liver failures 
(both 2 patients were 
classified as Child-
Pugh B before SBRT
3, 6 months after SBRT)
Takeda 
et al. [29]
2014 Retrospective 63 Child-Pugh A 
(69.8%): 40 Gy/5 fr
Child-Pugh B 
(30.2%): 35 Gy/5 fr
(70 or 80% 
isodose line, 
encompassing 
PTV)
Child-Pugh 
A: 72.0
Child-Pugh 
B: 59.5
31.1 1-year 100%
2-year 95%
3-year 92%
1-year 
76%
2-year 
87%
3-year 
73%
*n = 63
7.9% mild fatigue
15.8% G3 subacute 
liver toxicity (6.3% 
before SBRT)
*n = 63
20.6% G3 liver toxicity
Yamashita 
et al. [30]
2014 Retrospective 79 48 Gy/4 fr (40 
Gy/4 fr-60 Gy/10 
fr)
96 (75-106) 15.9 2-year
74.1%
2-year 
52.9%
n = 130 (79 HCC, 51 liver metastases)
2.3% G2 gastrointestinal toxicity (gastric 
inflammation in 2 patients 1 month after 
SBRT, gastric ulcer in 1 patient; 27 months 
after SBRT)
3.1% G3 gastrointestinal toxicity (duodenal 
ulcer 17 months, intestinal tract bleeding 
5, 6 months, transverse colon ulceration 5 
months, respectively, after SBRT)
0.8% G4 gastro-duodenal artery rupture (5 
months after SBRT)
0.8% chest wall pain (combined with TACE)
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Author 
[Ref]
Year Prospective/
retrospective
Patient 
number
Total dose/
fraction (median, 
range)
BED
10
 (Gy) Median 
follow-up 
(range) 
(months)
Local 
control
Overall 
survival
Adverse events
Acute response Late response
Culleton 
et al. [31]
2014 Prospective 29 34.4 (20.9–48.7) 
Gy/6 (5-15) fr 
(Mean dose to 
PTV ) or
30.9 (197-46.8) 
Gy/6 (5-15) fr 
(D95 prescription 
for PTV)
54.1 
(28.2–88.2)
46.8 
(26.2–83.3)
(Calculated 
presupposed 
with 6 
fractions)
NA 6-month 
69.7%
1-year
55.5%
1-year 
32.3%
(median 
7.9 
months)
48.3% G1-2 fatigue
20.7% G1 nausea
10.3% G1-2 vomiting
10.3% G1-2 diarrhea
10.3% G1 abdominal pain
10.3% G1-2 abdominal distension
Child-Pugh score progression (24.1, 
24.1, 10.3% by 1 point, 2 points, 3 points, 
respectively, at 1 month after SBRT)
17.2% G3 thrombocytopenia (3 months after 
SBRT)
6.9% G3, 3.4% G4 transaminase elevation (1 
month after SBRT)
3.4% G4 AST (3 months after SBRT)
Huertas 
et al. [32]
2015 Retrospective 77 (97 
HCC)
45 Gy/3 fr 
(prescribed to the 
80% isodose line, 
encompassing 
PTV)
112.5 12 1-year
99%
2-year 99%
1-year 
81.8%
2-year 
56.6%
1.3% G1, 1.3% G2 
asthenia
2.6% G1, 2.6% G2, 
1.3% G3 ascites
1.3% G1 rib pain
1.3% G1 anorexia
2.6% G1 nausea
3.9% G1 epigastric 
pain
1.3% Classic RILD
3.9% Non-classic 
RILD
1.3% G5 
Hematemesis
1.3% G2 asthenia
1.3% G1 radiation 
dermatitis
2.6% G1 nausea
2.6% G1, 3.9% G2, 3.9% 
G3 ascites
1.3% G2 colic ulcer
1.3% G3, 1.3% G4 
gastric ulcer
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Author 
[Ref]
Year Prospective/
retrospective
Patient 
number
Total dose/
fraction (median, 
range)
BED
10
 (Gy) Median 
follow-up 
(range) 
(months)
Local 
control
Overall 
survival
Adverse events
Acute response Late response
Takeda 
et al. [33]
2016 Prospective 90 Child-Pugh A: 40 
Gy/5 fr
Child-Pugh B: 35 
Gy/5 fr
(prescribed 
to the 60–80% 
isodose line, 
encompassing 
PTV, D95 
prescription for 
PTV)
Child-Pugh 
A: 72.0
Child-Pugh 
B: 59.5
41.7 3-year 96.3% 3-year 
66.7%
2.2% transaminase elevation
5.6% thrombocytopenia
8.9% Child-Pugh score progression (by two 
points)
Wahl et al. 
[34]
2016 Retrospective 63 30 or 50 Gy/3 
or 5 fr (D99.5 
prescription for 
PTV, the 75 to 
85% isodose line 
encompassing 
PTV
100 (NA) 13.0 1-year 97.4%
2-year 83.8%
1-year 
74.1%
2-year 
46.3%
1.6% G3 RILD
1.6% G3 
gastrointestinal 
bleeding
1.6% G3 worsening 
ascites
8.3% G3 luminal 
gastrointestinal toxicity 
(at 2 years after SBRT)
3.3% G3 biliary toxicity 
(at 2 years after SBRT)
*Child-Pugh score 
progression by average 
1.2 points) (at 12 
months after SBRT)
Su, et al. 
[35]
2017 Retrospective 82 42–48 Gy/3–5 fr
(67 (57–80) % 
isodose line 
encompassing 
PTV)
NA
(77.3–124.8) 
(Calculated 
presupposed 
with 42 Gy/5 
fr–48 Gy/3 fr)
33.0 NA (one 
patient 
experienced 
local 
progression) 
(PFS; 1-year 
81.4%, 
3-year 
50.2%,
5-year 40.7%
1-year 
96.3%
3-year 
81.8%
5-year 
70.0%
4.9% G1, 3.7% G2, 1.2% G3 nausea
1.2% G1, 1.2% G2, 2.4% G3 weight loss
3.7%, G1, 1.2% G2 fatigue
3.7% G1 hyperbilirubinemia
3.7% G1 ALT
4.9% G1 anemia
6.1%, 3.7% Child-Pugh progression (1, 2 
points, respectively)
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Author 
[Ref]
Year Prospective/
retrospective
Patient 
number
Total dose/
fraction (median, 
range)
BED
10
 (Gy) Median 
follow-up 
(range) 
(months)
Local 
control
Overall 
survival
Adverse events
Acute response Late response
Lo et al. 
[36]
2017 Retrospective 89 25–60 Gy/4-6 fr
(40 Gy/5 fr (19 
patients), 45 Gy/5 
fr (18 patients), 
50 Gy/5 fr (14 
patients))
72 (40 Gy/5 
fr), 85.5 (45 
Gy/5 fr),
100 (50 Gy/5 
fr)
NA 3-year 78.1% 1-year 
45.9%
3-year 
24.3%
24.7% G1, 4.5% G2 fatigue
13.5% G1, 2.2 G2 anorexia
13.5% G1, 12.4% G2, 1.1% G3 nausea/
vomiting
4.5% G1 abdominal distension
19.1 G1, 7.9% G2, 2.2% G3 abdominal pain
3.4% G2, 2.2% G3 gastritis/gastric ulcer
2.2% G1, 4.5% G2 duodenal ulcer
1.1% G1, 2.2% G2 diarrhea
1.1% G1, 2.2% G2 dermatitis
11.2% RILD (1.1% classic RILD, 9.0% 
non-classic RILD (including 2 patients 
developed fatal non-classic RILD), 1.1% 
fulfilled the criteria of both types)
Uemoto, 
et al. [37]
2018 Retrospective 121 (146 
HCCs)
45 (30–64) Gy/5 
(4-20) fr
80 (48–106) 21 2-year 
91.5%, 
5-year 89.8%
2-year 
73.7%, 
5-year 
57.0%
0.7≤G2, 0.7% G3 cholangiectasis
1.5% G1 pneumonitis
0.7% mucositis
0.7% G1 rib fracture
25.2% ascites
2.2 jaundice
1.5% pleural effusion (no hematological 
abnormality changed from the baselines)
Abbreviations: NA = not applicable, HCC = hepatocellular carcinoma, SBRT = stereotactic body radiation therapy, NA = not applicable; BED = biologically effective 
dose, G = grade, PTV = planning target volume, AST = aspartate transaminase elevation, ALT = alanine transaminase elevation, ALP = alkaline phosphatase elevation, 
PT-INR = prothrombin time-international normalized ratio prolongation, RILD = radiation-induced liver disease, TACE = transcatheter arterial chemoembolization, PFS 
= progression-free survival.
Table 2. Summary of studies of hepatocellular carcinoma.
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Figure 1. Local control and overall survival of HCC after SBRT. Local control (LC) and overall survival (OS) were 
described using the Kaplan Meier method in 100 patients with 116 HCCs underwent SBRT of BED
10
 ≥75 Gy in ≤10 
fractions, between July 2007 and August 2016 at Miyakojima IGRT Clinic (Osaka, Japan, approval no. 9). The 1-, 2- and 
3-year LC rate was 100.0, 95.4 and 93.5%, respectively. The 1-, 2- and 3-year OS rate was 83.7, 72.6 and 60.5%, respectively. 
Abbreviations: HCC, hepatocellular carcinoma; SBRT, stereotactic body radiation therapy.
Figure 2. Typical course of SBRT for HCC in cirrhotic liver. An 86-year-old man developed HCC in S8. HCC with 50 mm 
in diameter existed (A, contrast-enhanced CT, arrowhead). SBRT of 40 Gy in four fractions (BED
10
 = 80.0 Gy) (B, treatment 
plan). The high intensity area that observed before SBRT in diffusion-weighted imaging of MRI (C, left) disappeared 
three months after SBRT (C, right). Abbreviations: HCC, hepatocellular carcinoma; CT, computed tomography; MRI, 
magnetic resonance imaging; SBRT, stereotactic body radiation therapy; BED, biologically effective dose.
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4. Radiotherapy in the management of HCC with tumor thrombus in 
vessels
Portal vein tumor thrombosis (PVTT), the most common form of macrovascular invasion of 
HCC, could propagate further, obstruct the whole vein lumen, and lead to poor prognoses 
ranging from only 2 to 4 months after supportive care [44, 45]. One of the treatment modali-
ties is surgical resection that could lead to median survival time of 8–64 months, 1-, 2-, and 
3-year overall survival rates of 31–87, 0–76, and 0–71%, respectively [46]. In addition, there 
is a potential survival benefit by surgical resection [47]. However, tumor thrombectomy can 
be associated with high morbidity and mortality rates, up to 23.7% [48]. TACE might be con-
traindicated for HCC patients with PVTT because of the potential risk of hepatic ischemic 
damages due to TACE. In addition, PVTT is not an indication for RFA because of the potential 
cooling effect and challenging status of percutaneous intervention.
Figure 3. SBRT for PVTT. A 77-year-old man developed HCC due to hepatitis C with tumor thrombus in right portal 
vein (A, arrows, contrast-enhanced CT). The patient underwent SBRT of 60 Gy in 15 fractions (BED
10
 = 84.0 Gy) (B). The 
tumor thrombus disappeared after three months after SBRT. Contrast-enhanced CT indicates disobliteration of the right 
portal vein after SBRT (C, arrows). Abbreviations: SBRT, stereotactic body radiation therapy; PVTT, portal vein tumor 
thrombosis; HCC, hepatocellular carcinoma; CT, computed tomography; BED, biologically effective dose.
Management of Chronic Liver Diseases - Recent Advances96
Although the efficacy of radiotherapy has been reported in patients with tumor thrombus 
using conventional schedule, the evidence of the survival benefit is insufficiently strong 
[39–41, 49–51]. In addition, Lin et al. have reported that radiotherapy can recanalize at a rate 
of 79% in 14 patients with PVTT [51]. However, there are only a few comparison studies 
among the techniques of radiotherapy [39, 51]. Matsuo et al. have reported, in a retrospective 
study, that the response rate of PVTT or inferior vena cava tumor thrombosis to radiotherapy 
was 67 and 46% in SBRT and 3D-CRT groups, respectively (P = 0.04) [39]. Moreover, SBRT 
has an advantage with regard to the shortened treatment term. Radiotherapy including SBRT 
may have the potential to be the standard technique of radiotherapy in the treatment of PVTT. 
Figure 3 indicates a case of SBRT for HCC with PVTT.
Radiotherapy can overcome anatomical barriers such as major vessels and achieve a promising 
local control with minimal invasion. Therefore, a combined multimodal approach including 
radiotherapy would be needed in the treatment of the HCC with PVTT in order to maximize 
tumor control and to keep the normal liver damages due to treatment within a safe limit.
5. Prescription doses of SBRT for HCC
A dose-response relationship has been reported for conventional fractionated and stereotactic 
radiotherapy, although the best prescription dose of radiotherapy for HCC remains undecided 
[12, 27, 52].
Figure 4. Dose-response relationship in SBRT for HCC. Previous reports that clearly indicates 2-year local control 
and overall survival were plotted in the scatter diagram [20–24, 27–30, 32, 34, 37]. X- and Y-axis indicates total doses 
radiotherapy in term of BED
10
 and the rates of 2-year local control and overall survival, respectively. No apparent dose-
response relationship was observed in local control (r = 0.2828 and P = 0.3732) and overall survival (r = -0.1872 and P = 
0.5602) at 2 years after SBRT. Abbreviations: SBRT, stereotactic body radiation therapy; HCC, hepatocellular carcinoma; 
BED, biologically effective dose.
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Bae et al. reported 85% local control rates at 2 years after an SBRT of 50 Gy in 10 fractions, 75 Gy 
in terms of biologically effective dose (BED) using the linear-quadratic (LQ) model assuming 
an α/β = 10 Gy for tumors (BED
10
) [53]. Lausch et al. have reported that the administration 
of a biologically equivalent total dose in 2-Gy fractions (EQD2) of 84 Gy (BED
10
 = 100.8 Gy) 
could achieve a 90% probability of a 6-month local control [54]. Jang et al. estimated that a 90% 
probability of a 2-year local control required 51.1 Gy in three fractions (BED
10
 = 138.1 Gy) [27]. 
Sanuki et al. and Takeda et al. reported a more than 90% 3-year local control rate with 40 Gy in 
five fractions (BED
10
 = 72 Gy) that was intended to enclose the planning target volume (PTV) 
by 80% isodose line of the maximum dose [28, 29]. Figure 4 shows no dose–response relation-
ship between a 2-year local control and overall survival rates and the total BED of SBRT with 
the range of prescription doses of ≥72 Gy. Notably, previous reports include various prescrip-
tion definitions such as the prescription dose for the iso-center (isocentric prescription), a cer-
tain percent isodose line of the maximum dose (marginal prescription), and the dose to cover 
95% of the PTV (D95 prescription). Based on these data, HCC has been treated with ≥80 Gy of 
BED
10
 and achieved a good local control at our institute as we hypothesized [37].
6. Adverse events of SBRT for HCC in cirrhotic liver, risk factors, 
and prevention
Manifestations of liver SBRT toxicity have fatigue, damage to the liver, gastrointestinal tract 
and biliary duct, cytopenia, dermatitis, and rib fractures (Table 2) [18–37]. Adverse events of 
radiotherapy depend on the treatment site, and the irradiated doses and volume and are cat-
egorized into either acute (typically within 3 months of radiotherapy) or late (months to years 
after radiotherapy), based on their time of onset [55]. The acute phase of radiation-induced 
injury is characterized by inflammation, in response to therapy, while the late phase is charac-
terized by fibrosis and sclerosis of vessels leading to focal ischemia and chronic inflammation. 
To distinguish acute and late phases of toxicities is often difficult since liver damage with 
serum abnormalities can be observed weeks or months later after SBRT [16]. We summarize 
with focusing on the major toxicities in the liver, gastrointestinal tract, and central bile duct.
6.1. Liver toxicity
Liver toxicity, such as classic and non-classic radiation-induced liver disease (RILD), is one of 
the most common dose-limiting toxicities in liver radiotherapy [15, 16, 56, 57]. Clinical RILD 
occurs between 2 weeks and 7 months, typically within 4–8 weeks following hepatic radio-
therapy. The patient presents with fatigue, weight gain, increased abdominal girth, hepato-
megaly, anicteric ascites, and an elevation in alkaline phosphatase (over twice the upper limit 
of the  normal values). Treatment options for RILD are limited, and the condition can become 
fatal due to liver failure [56, 58–61]. Non-classic RILD occurs in patients with underlying 
chronic hepatic disease, such as cirrhosis and viral hepatitis, and is characterized by jaundice 
and/or markedly elevated serum transaminases (over five times the upper limit of the nor-
mal values), developing between 1 week and 3 months after the completion of hepatic radio-
therapy [19, 61]. The mean dose of less than 30 Gy has been considered as safe but radiation 
tolerance of the liver in a conventional radiotherapy [19]. However, the actual mean doses 
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appropriate for liver  irradiation in SBRT have not been adequately investigated. Furthermore, 
radiotherapy has the potential to reactivate hepatitis B virus and differentiating patients may 
be necessary [62, 63]. There are differences in radiosensitivity between patients with nor-
mal and cirrhotic livers; cirrhotic liver may yield a higher radiosensitivity than normal liver 
[16, 57]. In addition, Child-Pugh B, particularly scores of ≥8, was considered a significant risk 
factor for severe hepatic toxicity and poor prognosis [21, 31, 64]. Culleton et al. reported that 
63% of 29 HCC patients with Child-Pugh B or C, receiving SBRT, declined Child-Pugh score 
by two points after 3 months [31].
As the liver is widely accepted as a parallel organ, a part of it can receive a high dose of irra-
diation as long as the functions as a whole organ are preserved [65–67]. Indeed, Schefter et al., 
Olsen et al., and Kang et al. used dose constraint, as the liver volume was >700 mL when the 
dose administered was less than 15 and 17 Gy in three fractions [22, 68, 69]. However, intrahe-
patic recurrence often occurs after a radical treatment for liver tumors because of chronic liver 
diseases, and such tumors have a chance to receive second radical treatment [9, 70]. Thus, the 
prediction of the volume of liver dysfunction is essential in order to spare the residual liver 
volume. After SBRT, focal dysfunction was noted in the irradiated background liver. Sanuki 
et al. have shown that the threshold dose of focal liver dysfunction was 30 and 25 Gy in five 
fractions in patients with Child-Pugh A and B, respectively, using magnetic resonance imag-
ing (MRI) [71]. Similarly, Doi et al. have reported that focal liver dysfunction can occur at 40 
and 70 Gy of BED
2
 in the cirrhotic and normal liver, respectively, at a minimum dose [57]. 
Figure 5 indicates a focal liver damage 3 months after SBRT. We have presented SBRT strategy 
with checkpoints to ensure safe treatment modality in SBRT for liver tumor [72]. To prevent 
RILD-related mortality, we evaluate the mean doses for the liver first and then analyze the 
potential loss of hepatic function in terms of BED (Figure 6).
6.2. Gastrointestinal injury
Ionizing radiation exerts an anticancer effect by reacting with molecular oxygen and water 
to generate reactive oxygen species that can attack deoxyribose in deoxyribonucleic acid 
(DNA). Sublethal doses of radiation can cause non-repairable DNA damage [73]. Intestine is 
a radiosensitive tissue because of the rapid turnover rate, and this can be a dose-limiting fac-
tor in SBRT. Gastrointestinal injuries including bleeding, ulcers, and perforations have been 
described, and the incidence of symptomatic gastrointestinal toxicities was less than 10% in 
majority of the previous reports (Table 2). However, severe toxicities, which can be lethal, 
have also been described in SBRT in the upper abdomen including liver [22, 30, 74–76]. Kang 
et al. have highlighted the possible association between severe gastrointestinal toxicity and 
the existence of mucosal ulceration prior to radiotherapy [22]. Barney et al. reported that the 
combination of SBRT and vascular endothelial growth factor inhibitor increased the risk of 
grade 3 or greater gastrointestinal toxicities [77]. Careful assessment is therefore required 
prior to the implementation of combined treatments, such as targeted therapy.
For the prevention of severe gastrointestinal injury, analyses of dose-volume responses have 
been reported. Kopek et al. recommended V21Gy ≤1 cc for the duodenum in abdominal SBRT 
in their analyses in 29 patients with cholangiocellular carcinoma (CCC) underwent SBRT 
(45 Gy/3 fractions) [78]. Bae et al. concluded that Dmax of 35 and 38 Gy in three fractions was 
associated with a probability of 5 and 10% severe gastroduodenal toxicity, respectively [79]. 
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Kavanagh et al. recommended that the volume of stomach receiving >22.5 Gy should be ide-
ally minimized to <5 cc, with Dmax of <30 Gy in three fractions [80]. Sanuki et al. suggested 
that SBRT could be performed with the avoidance of severe toxicities when the target had a 
distance of >2 cm from the bowel [81]. An increased number of fractions may reduce BED for 
normal tissues in SBRT for liver tumors close to the gastrointestinal tract [57]. Since there are 
no established strategies for the prevention and treatment of radiation-induced gastrointestinal 
injury, efforts should be required to minimize radiation doses for gastrointestinal tracts [82].
6.3. Central hepatobiliary tract toxicity
Eriguchi et al. documented asymptomatic bile duct stenosis in 2/50 patients, receiving >20 Gy 
in five fractions to the central liver [83]. One of these patients received SBRT on two occa-
sions to the central liver tumors and developed abnormalities in liver enzymes. The abnormal 
region visible on a computed tomography scan corresponded to the site irradiated up to a 
cumulative maximum dose of 88 Gy in two sessions of SBRT. The authors concluded that 
SBRT for liver tumors in the hepatic hilum was feasible with minimal biliary toxicity.
Figure 5. Focal liver dysfunction after SBRT in the follow-up MRI. A 77-year-old woman developed HCC due to hepatitis B. 
(A) Contrast-enhanced CT images indicate HCC in S7 area. Arterial phase showed patchy high density area (arrow, 
left) and contrast washed-out was observed later in delayed phase (arrow, right). (B) SBRT of 55 Gy in 10 fractions 
(BED
10
 = 85.3 Gy) was performed for the tumor. (C) Low intensity area was found in accordance with the irradiated 
area of treatment plan in Gd-EOB-DTPA enhanced-MRI three months after SBRT (left, arrows) and focal liver atrophy 
was observed later (right, arrow). Abbreviations: SBRT, stereotactic body radiation therapy; MRI, magnetic resonance 
imaging; CT, computed tomography; HCC, hepatocellular carcinoma; BED, biologically effective dose; Gd-EOB-DTPA, 
gadolinium ethoxybenzyl-diethylenetriamine pentaacetic acid.
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Osmundson et al. analyzed 96 patients with liver tumors, including 20 CCCs, who received 
different schedules of SBRT, and reported that the incidence of hepatobiliary toxicity ≥Grade 
2 and 3 was 24.0 and 18.8%, respectively [84]. Furthermore, CCC, biliary stent, VBED1072 ≥ 21 cc, 
VBED1066 ≥ 24 cc, and DmeanBED10 ≥ 14 Gy to central hepatobiliary tract were associated with 
hepatobiliary toxicity [81]. The same groups reported radiation-induced pathological changes 
of the bile duct in resected surgical specimens 25 months after SBRT and concluded that liver 
toxicity should be considered while treating central liver lesions [85]. The same group has 
also reported a dose-volume association between ≥Grade 3 hepatobiliary toxicity and doses 
for central biliary tract and suggested VBED1040 < 37 cc and VBED1030 < 45 cc as dose-volume 
constraints in SBRT for primary liver tumors [86].
The anatomical structures in the hepatic hilum make radical treatment for liver tumors, such 
as surgery and RFA, more challenging. In such a scenario, SBRT can be a better option in com-
parison to other modalities, and to the best of our knowledge, there is no apparent consensus 
on the use of SBRT with few reports addressing this point. Further studies are required to 
determine the dose constraints for the bile duct, as there can be potential dose constraints due 
to the central hepatobiliary tract toxicity.
7. Current issues and future perspective of liver SBRT
Liver SBRT is a well-established and promising treatment for a limited number of small 
tumors. We have set out the difference between primary and metastatic liver cancers, consid-
ering the occurrence and prevention of toxicities. However, further questions regarding the 
pathological features of liver cancers, and potential SBRT strategies, including radiobiology-
based SBRT and SBRT combined with immunotherapy, have not yet been fully addressed.
Figure 6. The current recommended treatment protocol to provide a safe SBRT for HCC in cirrhotic liver. To minimize the 
risk of radiation-induced liver disease and liver damage, two different checkpoints were included. Herein, we propose a 
safe treatment protocol for SBRT of liver tumors. First, liver function is evaluated according to the Child–Pugh classification 
(Step 1). Next, the liver doses are evaluated to prevent RILD. A mean BED
2
 of less than 73 and 16 Gy for the whole 
liver should be maintained to prevent RILD in patients with Child–Pugh A and B liver function, respectively (Step 2). 
Finally, the volume of hepatic dysfunction is assessed to estimate the residual liver volume (Step 3). Abbreviations: SBRT, 
stereotactic body radiation therapy; HCC, hepatocellular carcinoma; BED, biologically effective dose.
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7.1. Potent strategies of SBRT based on radiation biology
Brown et al. reported that a greater endothelial cell damage and vascular damage, leading cancer 
cell apoptosis, can be caused by SBRT, and reoxygenation can increase antitumor effect in frac-
tionated radiotherapy [87]. Shibamoto et al. concluded that reoxygenation could be promoted 
by a 72-h break period in SBRT [88]. No prospective clinical trials exist in terms of evaluation of 
the benefit of a break in SBRT. However, a longer overall treatment time (e.g., 1–2 fractions per 
week: 2-week schedule) may yield better local control outcomes in SBRT [89, 90]. SBRT for larger 
tumors has still unclear roles and is challenging because they are usually in exclusion criterion. 
In addition, large tumor size (≥2–4 cm) has been reported to be a predictive factor for poor out-
comes after SBRT for HCC [23, 30, 32]. Further biological assessment might yield potential fac-
tors that improve treatment outcomes such as escalated doses, treatment schedule with a break, 
combined therapy with ideal chemotherapy, individualized treatment, and particle therapies.
7.2. Potential needs of clinical tumor volume margin in liver SBRT
Definition of clinical tumor volume (CTV) is the volume that includes both gross and microscopic 
disease and is created by adding several mm to 1.5 cm to gross tumor volume (GTV), in order 
to allow for microscopic extension. However, CTV is frequently equal to GTV in SBRT [91]. It is 
still poorly understood whether CTV margins are necessary, as there are limited reports of micro-
scopic extension of liver tumors as premises for radiotherapy. HCC is characterized by direct 
invasion and a potential high presence of daughter nodules around the tumor that may lead to 
locoregional recurrence [92]. Wang et al. reported that the potential maximum margin extending 
beyond the gross tumor margin was 8.0 mm, although 94.7% of patients with HCC had a micro-
scopic extension of ≤3.5 mm [93]. Wang et al. analyzed 149 resected HCCs with a mean diameter 
of 5.8 cm (range: 1.0–22.0 cm) and found that microinvasion was not present in 47.0% patients 
[94]. Microinvasion distances of ≤2 mm were found in 96.1% of patients with tumor dimensions of 
≤5 cm. Uemoto et al. have first reported that a larger margin to GTV inclined to improve local con-
trol and survival outcomes in clinical data, suggesting the benefit of CTV margins [37]. Further 
clinical translational studies should be conducted in order to assess the optimal CTV margins.
7.3. Current knowledge of Immuno-SBRT
Regression of tumors outside the radiation field after local radiotherapy, due to systemic induc-
tion of antitumor immunity, is called the abscopal effect [95]. SBRT combined with immune 
checkpoint inhibitor has recently resulted in unexpected clinical complete responses from 
distant sites from the irradiated areas, in various malignancies [96–98]. Recently, synergistic 
effects of radiotherapy combined with immunotherapy have been reported in both preclinical 
and clinical studies, with the high possibility of the abscopal effect, which may significantly 
change the treatment strategies for metastatic diseases [96–105]. However, the optimal treat-
ment schedule and doses in the combined setting of radiotherapy and immunotherapy are 
poorly understood at present. Young et al. reported an enhanced efficacy of immune-radio-
therapy administered concurrently with radiotherapy [101]. In a meta-analysis of preclinical 
data, Marconi et al. reported that the probability of abscopal effects is 50% when a BED of 
60 Gy is generated [102]. Moreover, SBRT may provide smaller target volumes, and in a clini-
cal trial involving patients with pancreatic cancer, Wild et al. found that  hypofractionation 
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could minimize the toxic effects on circulating lymphocytes [106]. By expanding its applica-
tion range from small tumors to metastases, SBRT might have good potential to achieve newer 
objectives in systematic disease, although further investigations are required.
8. Advantages of particle therapy in treatment for HCC in cirrhotic 
liver
The use of particle therapy, such as proton and carbon ion therapy for liver tumors, is a 
promising strategy to increase the dose of radiation without a concurrent increase in toxicity. 
Particle therapy exhibits a narrow Bragg peak at a defined depth for a defined energy [73]. 
Particle therapy can provide high concentrations of radiation doses to the target by position-
ing individual Bragg peaks to coincide with the areas of the target. In photon radiotherapy, 
the doses that the liver receives have a strong positive relationship with the irradiated target 
volume, and unacceptable higher doses might be irradiating to the background liver in the 
treatment of large live tumors [72]. Particle therapy can reduce the liver volume that receives 
low to intermediate doses, resulting in the reduction of mean liver doses with an advantage of 
target conformity [107, 108]. In addition, carbon ion therapy offers the added potential benefit 
of an increased relative biological effectiveness and a lower oxygen enhancement ratio due 
to the high linear energy transfer that may improve responses in hypoxic areas of tumors, 
which are more resistant to photon radiotherapy [73]. A relevant clinical consideration is that 
particle therapy can benefit relatively large tumors, such as >3 cm (particularly >5 cm) and 
patients with poor liver function, which are limiting for SBRT [109].
9. Conclusions
For HCC, SBRT is safe and effective, with excellent local control achieved. Tumors that are 
relatively small and distant from gastrointestinal tissues are strong candidate for SBRT in 
curative intent. Therefore, novel strategies should be developed based on new knowledge 
of biological responses to radiation therapy. State-of-the-art liver SBRT remains a pioneering 
strategy in multimodal therapy.
Acknowledgements
The authors would like to thank Messrs. Kenji Uemoto, Norihisa Masai, Koichi Yamada, and 
Daisaku Tatsumi from Miyakojima IGRT Clinic (Osaka, Japan).
This work was supported by Grant-in-Aid for Young Scientists (B) Grant Number 17 K16493.
Conflict of interest
None.
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Cirrhotic Liver
http://dx.doi.org/10.5772/intechopen.76505
103
Author details
Hiroshi Doi1,2*, Hiroya Shiomi1 and Ryoong-Jin Oh1
*Address all correspondence to: h-doi@med.kindai.ac.jp
1 Miyakojima IGRT Clinic, Osaka, Japan
2 Department of Radiation Oncology, Kindai University Faculty of Medicine, Osaka, Japan
References
[1] Stuver S, Trichopoulos D. Cancer of the liver and biliary tract. In: Adami HO, Hunter D, 
Trichopoulos D, editors. Textbook of Cancer Epidemiology. 2nd ed. New York: Oxford 
University Press; 2008
[2] World Health Organization, International Agency for Research on Cancer. Estimated 
Cancer Incidence, Mortality and Prevalence Worldwide in 2012 [Internet]. Available 
from: http://globocan.iarc.fr/Default.aspx. [Accessed: December 4, 2017]
[3] El-Serag HB. Hepatocellular carcinoma. The New England Journal of Medicine. 
2011;365:1118-1127
[4] Zhang DY, Friedman SL. Fibrosis-dependent mechanisms of hepatocarcinogenesis. 
Hepatology. 2012;56:769-775
[5] Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, et al. Alcohol and 
hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in 
men and women. American Journal of Epidemiology. 2002;155:323-331
[6] Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: 
Incidence and risk factors. Gastroenterology. 2004;127(5, Suppl 1):S35-S50
[7] Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of 
patients with hepatocellular carcinoma. Gastroenterology. 2016;150:835-853
[8] Soyama A, Eguchi S, Egawa H. Liver transplantation in Japan. Liver Transplantation. 
2016;22:1401-1407
[9] Tateishi R, Shiina S, Yoshida H, Teratani T, Obi S, Yamashiki N, Yoshida H, Akamatsu M, 
Kawabe T, Omata M. Prediction of recurrence of hepatocellular carcinoma after curative 
ablation using three tumor markers. Hepatology. 2006;44:1518-1527
[10] Zeng Z-C, Fan J, Tang Z-Y, Zhou J, Qin L-X, Wang J-H, et al. A comparison of treatment 
combinations with and without radiotherapy for hepatocellular carcinoma with por-
tal vein and/or inferior vena cava tumor thrombus. International Journal of Radiation 
Oncology Biology Physics. 2005;61(2):432-443
[11] Park W, Lim D-H, Paik SW, Koh KC, Choi MS, Park CK, et al. Local radiotherapy for 
patients with unresectable hepatocellular carcinoma. International Journal of Radiation 
Oncology Biology Physics. 2005 Mar 15;61(4):1143-1150
Management of Chronic Liver Diseases - Recent Advances104
[12] Park HC, Seong J, Han KH, Chon CY, Moon YM, Suh CO. Dose-response relationship 
in local radiotherapy for hepatocellular carcinoma. International Journal of Radiation 
Oncology Biology Physics. 2002;54:150-155
[13] Ben-josef E, Lawrence TS. Radiotherapy for unresectable hepatic malignancies. Seminars 
in Radiation Oncology. 2005 Oct;15(4):273-278
[14] Fuss M, Salter BJ, Herman TS, Thomas CR. External beam radiation therapy for hepato-
cellular carcinoma: Potential of intensity-modulated and image-guided radiation ther-
apy. Gastroenterology. 2004 Nov;127(5 Suppl 1):S206-S217
[15] Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, 
Wesson M. Tolerance of normal tissue to therapeutic irradiation. International Journal 
of Radiation Oncology, Biology, Physics. 1991;21:109-122
[16] Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, Ten Haken RK. Radiation-
associated liver injury. International Journal of Radiation Oncology, Biology, Physics 
2010;76:S94-100
[17] Blomgren H, Lax I, Näslund I, et al. Stereotactic high dose fraction radiation therapy 
of extracranial tumors using an accelerator: Clinical experience of the first thirty-one 
patients. Acta Oncologica. 1995;34:861-870
[18] Wulf J, Guckenberger M, Haedinger U, et al. Stereotactic radiotherapy of primary liver 
cancer and hepatic metastases. Acta Oncologica. 2006;45:838-847
[19] Kwon JH, Bae SH, Kim JY, et al. Long-term effect of stereotactic body radiation therapy 
for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical 
resection. Stereotactic radiotherapy for liver cancer. BMC Cancer. 2010;10:S27-S10
[20] Seo YS, Kim MS, Yoo SY, et al. Preliminary result of stereotactic body radiotherapy as 
a local salvage treatment for inoperable hepatocellular carcinoma. Journal of Surgical 
Oncology. 2010;102:209-214
[21] Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, Johnstone PA, Cardenes 
HR. Stereotactic body radiotherapy for primary hepatocellular carcinoma. International 
Journal of Radiation Oncology, Biology, Physics. 2011;81:e447-e453
[22] Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, Bae SH, Jung DH, Kim KB, Lee 
DH, Han CJ, Kim J, Park SC, Kim YH. Stereotactic body radiation therapy for inoper-
able hepatocellular carcinoma as a local salvage treatment after incomplete transarterial 
chemoembolization. Cancer. 2012;118:5424-5431
[23] Huang WY, Jen YM, Lee MS, et al. Stereotactic body radiation therapy in recurrent hepa-
tocellular carcinoma. International Journal of Radiation Oncology, Biology, Physics. 
2012;84:355-361
[24] Honda Y, Kimura T, Aikata H, et al. Stereotactic body radiation therapy combined with 
transcatheter arterial chemoembolization for small hepatocellular carcinoma. Journal of 
Gastroenterology and Hepatology. 2013;28:530-536
[25] Bae SH, Kim MS, Cho CK, Kim KB, Lee DH, Han CJ, Park SC, Kim YH. Feasibility and 
efficacy of stereotactic ablative radiotherapy for barcelona clinic liver cancer-C stage 
hepatocellular carcinoma. Journal of Korean Medical Science. 2013;28:213-217
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Cirrhotic Liver
http://dx.doi.org/10.5772/intechopen.76505
105
[26] Bujold A, Massey CA, Kim JJ, et al. Sequential phase I and II trials of stereotactic 
body radiotherapy for locally advanced hepatocellular carcinoma. Journal of Clinical 
Oncology. 2013;31:1631-1639
[27] Jang WI, Kim MS, Bae SH, et al. High-dose stereotactic body radiotherapy correlates 
increased local control and overall survival in patients with inoperable hepatocellular 
carcinoma. Radiation Oncology. 2013;8:250
[28] Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, Iwabuchi S, Kunieda 
E. Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective 
outcome analysis in 185 patients. Acta Oncologica. 2014;53:399-404
[29] Takeda A, Sanuki N, Eriguchi T, Kobayashi T, Iwabutchi S, Matsunaga K, Mizuno T, 
Yashiro K, Nisimura S, Kunieda E. Stereotactic ablative body radiotherapy for previ-
ously untreated solitary hepatocellular carcinoma. Journal of Gastroenterology and 
Hepatology. 2014;29:372-379
[30] Yamashita H, Onishi H, Matsumoto Y, Murakami N, Matsuo Y, Nomiya T, Nakagawa 
K. Local effect of stereotactic body radiotherapy for primary and metastatic liver tumors 
in 130 Japanese patients. Radiation Oncology. 2014;9:112
[31] Culleton S, Jiang H, Haddad CR, Kim J, Brierley J, Brade A, Ringash J, Dawson 
LA. Outcomes following definitive stereotactic body radiotherapy for patients with Child-
Pugh B or C hepatocellular carcinoma. Radiotherapy and Oncology. 2014;111:412-417
[32] Huertas A, Baumann AS, Saunier-Kubs F, et al. Stereotactic body radiation therapy 
as an ablative treatment for inoperable hepatocellular carcinoma. Radiotherapy and 
Oncology. 2015;115:211-216
[33] Takeda A, Sanuki N, Tsurugai Y, et al. Phase 2 study of stereotactic body radiotherapy 
and optional transarterial chemoembolization for solitary hepatocellular carcinoma not 
amenable to resection and radiofrequency ablation. Cancer. 2016;122:2041-2049
[34] Wahl DR, Stenmark MH, Tao Y, Pollom EL, Caoili EM, Lawrence TS, Schipper MJ, Feng 
M. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for hepa-
tocellular carcinoma. Journal of Clinical Oncology. 2016;34:452-459
[35] Su TS, Liang P, Liang J, et al. Long-term survival analysis of stereotactic ablative radio-
therapy versus liver resection for small hepatocellular carcinoma. International Journal 
of Radiation Oncology, Biology, Physics. 2017;98:639-646
[36] Lo CH, Yang JF, Liu MY, et al. Survival and prognostic factors for patients with 
advanced hepatocellular carcinoma after stereotactic ablative radiotherapy. PLoS One. 
2017;12:e0177793
[37] Uemoto K, Doi H, Shiomi H, Yamada K, Tatsumi D, Yasumoto T, Takashina M, Koizumi 
M, Oh RJ. Clinical assessment of micro-residual tumors during stereotactic body radia-
tion therapy for hepatocellular carcinoma. Anticancer Research. 2018;38:945-954
[38] Nugent FW, Qamar A, Stuart KE, Galuski K, Flacke S, Molgaard C, Gordon F, Iqbal S, 
Hunter KU, Hartnett E, Gunturu K. A randomized phase II study of individualized ste-
reotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) 
Management of Chronic Liver Diseases - Recent Advances106
with DEBDOX beads as a bridge to transplant in hepatocellular carcinoma (HCC). In: 
2017 Gastrointestinal Cancer Symposium; Jan 19-21; San Fransisco, CA, USA; 2017. 223
[39] Matsuo Y, Yoshida K, Nishimura H, Ejima Y, Miyawaki D, Uezono H, Ishihara T, 
Mayahara H, Fukumoto T, Ku Y, Yamaguchi M, Sugimoto K, Sasaki R. Efficacy of 
stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor 
thrombosis/inferior vena cava tumor thrombosis: Evaluation by comparison with con-
ventional three-dimensional conformal radiotherapy. Journal of Radiation Research. 
2016;57:512-523
[40] Xi M, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ, Deng XW, Huang XY, Liu 
MZ. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with 
portal vein and/or inferior vena cava tumor thrombosis. PLoS One. 2013;8:e63864
[41] Zheng X-K, Chen L-H, Yan X, Wang H-M. Impact of prolonged fraction dose-delivery 
time modeling intensity-modulated radiation therapy on hepatocellular carcinoma cell 
killing. WJG. 2005 Mar 14;11(10):1452-1456
[42] Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: The 
report of AAPM task group 101. Medical Physics. 2010;37:4078-4101
[43] Timmerman RD, Herman J, Chinsoo Cho L. Emergence of stereotactic body radia-
tion therapy and its impact on current and future clinical practice. Journal of Clinical 
Oncology. 2014;32:2847-2854
[44] Yin J, Bo W-T, Sun J, Xiang X, Lang J-Y, Zhong J-H, et al. New evidence and perspec-
tives on the management of hepatocellular carcinoma with portal vein tumor thrombus. 
Journal of Clinical and Translational Hepatology. 2017 Jun 28;5(2):169-176
[45] Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepa-
tocellular carcinoma in Central Europe: Prognostic features and survival. Gut. 2001;48: 
103-109
[46] Jiang J-F, Lao Y-C, Yuan B-H, Yin J, Liu X, Chen L, et al. Treatment of hepatocellular 
carcinoma with portal vein tumor thrombus: Advances and challenges. Oncotarget. 2017 
May 16;8(20):33911-33921
[47] Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, et al. Survival 
benefit of liver resection for hepatocellular carcinoma associated with portal vein inva-
sion. Journal of Hepatology. 2016 Nov;65(5):938-943
[48] Tang Q-H, Li A-J, Yang G-M, Lai ECH, Zhou W-P, Jiang Z-H, et al. Surgical resection 
versus conformal radiotherapy combined with TACE for resectable hepatocellular carci-
noma with portal vein tumor thrombus: A comparative study. World Journal of Surgery. 
2013 Jun;37(6):1362-1370 Oncotarget; 2017
[49] Chan SL, Chong CCN, Chan AWH, Poon DMC, Chok KSH. Management of hepatocel-
lular carcinoma with portal vein tumor thrombosis: Review and update at 2016. WJG. 
2016 Aug 28;22(32):7289-7300
[50] Choi BO, Choi IB, Jang HS, et al. Stereotactic body radiation therapy with or without 
transarterial chemoembolization for patients with primary hepatocellular carcinoma: 
Preliminary analysis. BMC Cancer. 2008;8:351
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Cirrhotic Liver
http://dx.doi.org/10.5772/intechopen.76505
107
[51] Lin CS, Jen YM, Chiu SY, et al. Treatment of portal vein tumor thrombosis of hepatoma 
patients with either stereotactic radiotherapy or three-dimensional conformal radiother-
apy. Japanese Journal of Clinical Oncology. 2006;36:212-217
[52] Goodman KA, Wiegner EA, Maturen KE, et al. Dose-escalation study of single-fraction 
stereotactic body radiotherapy for liver malignancies. International Journal of Radiation 
Oncology, Biology, Physics. 2010;78:486-493
[53] Bae SH, Park HC, Lim DH, et al. Salvage treatment with hypofractionated radiother-
apy in patients with recurrent small hepatocellular carcinoma. International Journal of 
Radiation Oncology, Biology, Physics. 2012;82:e603-e607
[54] Lausch A, Sinclair K, Lock M, et al. Determination and comparison of radiotherapy dose 
responses for hepatocellular carcinoma and metastatic colorectal liver tumours. The 
British Journal of Radiology. 2013;86:20130147
[55] Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group 
(RTOG) and the European Organization for Research and Treatment of cancer (EORTC). 
International Journal of Radiation Oncology, Biology, Physics. 1995;31:1341-1346
[56] Jackson A, Haken Ten RK, Robertson JM, et al. Analysis of clinical complication data for 
radiation hepatitis using a parallel architecture model. International Journal of Radiation 
Oncology, Biology, Physics. 1995;31:883-891
[57] Doi H, Shiomi H, Masai N, Tatsumi D, Igura T, Imai Y, Oh RJ. Threshold doses and pre-
diction of visually apparent liver dysfunction after stereotactic body radiation therapy 
in cirrhotic and normal livers using magnetic resonance imaging. Journal of Radiation 
Research. 2016;57:294-300
[58] Dawson LA, Ten Haken RK, Lawrence TS. Partial irradiation of the liver. Seminars in 
Radiation Oncology 2001;11:240-246
[59] Ohara K, Okumura T, Tsuji H, et al. Radiation tolerance of cirrhotic livers in relation 
to the preserved functional capacity: Analysis of patients with hepatocellular carci-
noma treated by focused proton beam radiotherapy. International Journal of Radiation 
Oncology, Biology, Physics. 1997;38:367-372
[60] Cheng JCH, Wu JK, Huang CM, et al. Radiation-induced liver disease after three-dimen-
sional conformal radiotherapy for patients with hepatocellular carcinoma: Dosimetric 
analysis and implication. International Journal of Radiation Oncology, Biology, Physics. 
2002;54:156-162
[61] Xu ZY, Liang SX, Zhu J, Zhu XD, Zhao JD, Lu HJ, Yang YL, Chen L, Wang AY, Fu XL, 
Jiang GL. Prediction of radiation-induced liver disease by Lyman normal-tissue com-
plication probability model in three-dimensional conformal radiation therapy for pri-
mary liver carcinoma. International Journal of Radiation Oncology, Biology, Physics. 
2006;65:189-195
[62] Chou CH, Chen PJ, Lee PH, et al. Radiation-induced hepatitis B virus reactivation in 
liver mediated by the bystander effect from irradiated endothelial cells. Clinical Cancer 
Research. 2007;13:851-857
Management of Chronic Liver Diseases - Recent Advances108
[63] Kim JH, Park JW, Kim TH, et al. Hepatitis B virus reactivation after three-dimensional 
conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carci-
noma. International Journal of Radiation Oncology, Biology, Physics. 2007;69:813-819
[64] Cardenes HR, Price TR, Perkins SM, et al. Phase I feasibility trial of stereotactic body 
radiation therapy for primary hepatocellular carcinoma. Clinical & Translational 
Oncology. 2010;12:218-225
[65] Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. The American 
Journal of Roentgenology, Radium Therapy, and Nuclear Medicine. 1965;93:200-208
[66] Lawrence TS, Haken Ten RK, et al. The use of 3-D dose volume analysis to predict 
radiation hepatitis. International Journal of Radiation Oncology, Biology, Physics. 
1992;23:781-788
[67] Withers HR, Taylor JM, Maciejewski B. Treatment volume and tissue tolerance. 
International Journal of Radiation Oncology, Biology, Physics. 1988;14:751-759
[68] Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase 
I trial of stereotactic body radiation therapy (SBRT) for liver metastases. International 
Journal of Radiation Oncology, Biology, Physics. 2005;62:1371-1378
[69] Olsen CC, Welsh J, Kavanagh BD, Franklin W, McCarter M, Cardenes HR, Gaspar LE, 
Schefter TE. Microscopic and macroscopic tumor and parenchymal effects of liver ste-
reotactic body radiotherapy. International Journal of Radiation Oncology, Biology, 
Physics. 2009;73:1414-1424
[70] Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepato-
cellular carcinoma: National surveillance program of cirrhotic and non-cirrhotic patients 
with chronic hepatitis C in Japan. IHIT study group. Inhibition of Hepatocarcinogenesis 
by interferon therapy. Annals of Internal Medicine. 1999;131:174-181
[71] Sanuki N, Takeda A, Oku Y, Eriguchi T, Nishimura S, Aoki Y, Mizuno T, Iwabuchi S, 
Kunieda E. Threshold doses for focal liver reaction after stereotactic ablative body radia-
tion therapy for small hepatocellular carcinoma depend on liver function: Evaluation 
on magnetic resonance imaging with Gd-EOB-DTPA. International Journal of Radiation 
Oncology, Biology, Physics. 2014;88:306-311
[72] Doi H, Masai N, Uemoto K, Suzuki O, Shiomi H, Tatsumi D, Oh RJ. Validation of the 
liver mean dose in terms of the biological effective dose for the prevention of radiation-
induced liver damage. Reports of Practical Oncology and Radiotherapy. 2017;22:303-309
[73] Hall EJ, Giaccia AJ. Radiobiology for the Radiologist. 7th ed. Philadelphia: Lippincott 
Williams & Wilkins; 2011
[74] Høyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, Kiil Berthelsen 
A, Grau C, Aage Engelholm S, Von der Maase H. Phase II study on stereotactic body 
radiotherapy of colorectal metastases. Acta Oncologica. 2006;45:823-830
[75] Høyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally 
advanced pancreatic carcinoma. Radiotherapy and Oncology. 2005;76:48-53
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Cirrhotic Liver
http://dx.doi.org/10.5772/intechopen.76505
109
[76] Onishi H, Ozaki M, Kuriyama K, et al. Serious gastric ulcer event after stereotactic body 
radiotherapy (SBRT) delivered with concomitant vinorelbine in a patient with left adre-
nal metastasis of lung cancer. Acta Oncologica. 2012;51:624-628
[77] Barney BM, Markovic SN, Laack NN, et al. Increased bowel toxicity in patients treated 
with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radi-
ation therapy (SBRT). International Journal of Radiation Oncology, Biology, Physics. 
2013;87:73-80
[78] Kopek N, Holt MI, Hansen AT, et al. Stereotactic body radiotherapy for unresectable 
cholangiocarcinoma. Radiotherapy and Oncology. 2010;94:47-52
[79] Bae SH, Kim MS, Cho CK, Kang JK, Lee SY, Lee KN, Lee DH, Han CJ, Yang KY, Kim 
SB. Predictor of severe gastroduodenal toxicity after stereotactic body radiotherapy for 
abdominopelvic malignancies. International Journal of Radiation Oncology, Biology, 
Physics. 2012;84:e469-e474
[80] Kavanagh BD, Pan CC, Dawson LA, Das SK, Li XA, Ten Haken RK, Miften M. Radiation 
dose-volume effects in the stomach and small bowel. International Journal of Radiation 
Oncology, Biology, Physics. 2010;76:S101-S107
[81] Sanuki N, Takeda A, Kunieda E. Role of stereotactic body radiation therapy for hepato-
cellular carcinoma. World Journal of Gastroenterology. 2014;20:3100-3111
[82] Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the 
management of mucositis secondary to cancer therapy. Cancer. 2014;120:1453-1461
[83] Eriguchi T, Takeda A, Sanuki N, Oku Y, Aoki Y, Shigematsu N, Kunieda E. Acceptable 
toxicity after stereotactic body radiation therapy for liver tumors adjacent to the cen-
tral biliary system. International Journal of Radiation Oncology, Biology, Physics. 
2013;85:1006-1011
[84] Osmundson EC, Wu Y, Luxton G, Bazan JG, Koong AC, Chang DT. Predictors of toxic-
ity associated with stereotactic body radiation therapy to the central hepatobiliary tract. 
International Journal of Radiation Oncology, Biology, Physics. 2015;91:986-994
[85] Shaffer JL, Osmundson EC, Visser BC, Longacre TA, Koong AC, Chang DT. Stereotactic 
body radiation therapy and central liver toxicity: A case report. Practical Radiation 
Oncology. 2015;5:282-285
[86] Toesca DAS, Osmundson EC, Eyben RV, Shaffer JL, Lu P, Koong AC, Chang DT. Central 
liver toxicity after SBRT: An expanded analysis and predictive nomogram. Radiotherapy 
and Oncology. 2017;122:130-136
[87] Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: Are more 
than the 5 Rs involved? International Journal of Radiation Oncology, Biology, Physics. 
2014;88:254-262
[88] Shibamoto Y, Miyakawa A, Otsuka S, Iwata H. Radiobiology of hypofractionated stereo-
tactic radiotherapy: What are the optimal fractionation schedules? Journal of Radiation 
Research. 2016;57:i76-i82
Management of Chronic Liver Diseases - Recent Advances110
[89] Shibamoto Y, Hashizume C, Baba F, et al. Stereotactic body radiotherapy using a radio-
biology-based regimen for stage I non-small-cell lung cancer: Five-year mature results. 
Journal of Thoracic Oncology. 2015;10:960-964
[90] Matsuo Y, Shibuya K, Nagata Y, et al. Prognostic factors in stereotactic body radio-
therapy for non-small-cell lung cancer. International Journal of Radiation Oncology, 
Biology, Physics. 2011;79:1104-1111
[91] Nagata Y, editor. Stereotactic Body Radiation Therapy: Principles and Practices. 1st ed. 
Tokyo: Springer; 2015
[92] Jwo SC, Chiu JH, Chau GY, et al. Risk factors linked to tumor recurrence of human 
hepatocellular carcinoma after hepatic resection. Hepatology. 1992;16:1367-1371
[93] Wang W, Feng X, Zhang T, Jin J, Wang S, Liu Y, et al. Prospective evaluation of micro-
scopic extension using whole-mount preparation in patients with hepatocellular car-
cinoma: Definition of clinical target volume for radiotherapy. Radiation Oncology. 
2010;5:73
[94] Wang MH, Ji Y, Zeng ZC, et al. Impact factors for microinvasion in patients with hepa-
tocellular carcinoma: Possible application to the definition of clinical tumor volume. 
International Journal of Radiation Oncology, Biology, Physics. 2010;76:467-476
[95] Le QT, Shirato H, Giaccia AJ, et al. Emerging treatment paradigms in radiation oncol-
ogy. Clinical Cancer Research. 2015;21:3393-3401
[96] Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect 
in a patient with melanoma. The New England Journal of Medicine. 2012;366:925-931
[97] Hiniker SM, Chen DS, Reddy S, et al. A systemic complete response of metastatic mela-
noma to local radiation and immunotherapy. Translational Oncology. 2012;5:404-407
[98] Golden EB, Demaria S, Schiff PB, et al. An abscopal response to radiation and ipili-
mumab in a patient with metastatic non-small cell lung cancer. Cancer Immunology 
Research. 2013;1:365-372
[99] Hiniker SM, Reddy SA, Maecker HT, et al. A prospective clinical trial combining radia-
tion therapy with systemic immunotherapy in metastatic melanoma. International 
Journal of Radiation Oncology, Biology, Physics. 2016;96:578-588
[100] Seung SK, Curti BD, Crittenden M, et al. Phase 1 study of stereotactic body radio-
therapy and interleukin-2–tumor and immunological responses. Science Translational 
Medicine. 2012;4:137ra74
[101] Young KH, Baird JR, Savage T, et al. Optimizing timing of immunotherapy improves 
control of tumors by hypofractionated radiation therapy. PLoS One. 2016;11:e0157164
[102] Marconi R, Strolin S. Bossi et al. a meta-analysis of the abscopal effect in preclini-
cal models: Is the biologically effective dose a relevant physical trigger? PLoS One. 
2017;12:e0171559
[103] Shehade H, Kariolis MS, Stehr H, et al. Reprogramming the immunological microenvi-
ronment through radiation and targeting Axl. Nature Communications. 2016;7:13898
Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Cirrhotic Liver
http://dx.doi.org/10.5772/intechopen.76505
111
[104] Twyman-Saint Victor C, Rech AJ, et al. Radiation and dual checkpoint blockade activate 
non-redundant immune mechanisms in cancer. Nature. 2015;520:373-377
[105] Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergisti-
cally promote antitumor immunity in mice. The Journal of Clinical Investigation. 
2014;124:687-695
[106] Wild AT, Herman JM, Dholakia AS, et al. Lymphocyte-sparing effect of stereotactic 
body radiation therapy in patients with Unresectable pancreatic cancer. International 
Journal of Radiation Oncology, Biology, Physics. 2016;94:571-579
[107] Abe T, Saitoh JI, Kobayashi D, et al. Dosimetric comparison of carbon ion radiotherapy 
and stereotactic body radiotherapy with photon beams for the treatment of hepatocel-
lular carcinoma. Radiation Oncology. 2015;10:187
[108] Toramatsu C, Katoh N, Shimizu S, Nihongi H, Matsuura T, Takao S, Miyamoto N, 
Suzuki R, Sutherland K, Kinoshita R, Onimaru R, Ishikawa M, Umegaki K, Shirato 
H. What is the appropriate size criterion for proton radiotherapy for hepatocellular 
carcinoma? A dosimetric comparison of spot-scanning proton therapy versus intensity-
modulated radiation therapy. Radiation Oncology. 2013;8:48
[109] Mizumoto M, Oshiro Y, Okumura T. Proton beam therapy for hepatocellular car-
cinoma: A review of the University of Tsukuba experience. International Journal of 
Particle Therapy. 2016;2:570-578
Management of Chronic Liver Diseases - Recent Advances112
